ONCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oncolytics Biotech Inc (ONCY) does not present a strong buy opportunity at this time for a beginner, long-term investor with $50,000-$100,000 available. The technical indicators are bearish, there are no significant trading trends or positive news catalysts, and the financial performance, while showing improvement in net income, remains weak overall. Given the lack of strong positive signals, holding off on this stock is recommended.
The technical indicators for ONCY are bearish. The MACD is negative and expanding downward, RSI is neutral at 28.886, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 0.967, with support at 0.913 and resistance at 1.02.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
Bearish technical indicators, weak financial performance despite some improvement in net income, and no recent news or trading activity to drive positive sentiment.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of $14.4M (though improved by 50.9% YoY), and an EPS of -0.14 (improved by 16.67% YoY). Gross margin remains at 0%. Overall, financials show improvement but remain weak.
No analyst rating or price target changes provided.
